drugset / Trial / NCT00665496

A Study to Investigate the Time to Onset of Action of 10 mg and 20 mg of Vardenafil Compared to Placebo in Males With Erectile Dysfunction

NCT00665496

Phase 3 Completed 732 enrolled Bayer
RandomizedParallel-groupDouble-blindTreatment

Summary

This purpose of the study was to evaluate the earliest time to onset of action in adults with erectile dysfunction (often called impotence). In this study vardenafil has been compared to placebo. Patients were asked to fill in questionnaires and a diary in which they filled in details about attempts at sexual activity during study period. Patients received also a stopwatch to record the time of onset of erection. Stopwatch should be started immediately prior to initiating sexual activity and stopped when an erection perceived to be adequate for penetration was obtained.

Timeline

Start
2003-06
Primary completion
Completion
2003-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Vardenafil Small molecule 10 mg Oral
Subject Vardenafil Small molecule 20 mg Oral

Indications